BỘ KHOA HỌC VÀ CÔNG NGHỆ
HỆ THỐNG THÔNG TIN QUỐC GIA VỀ KHOA HỌC, CÔNG NGHỆ VÀ ĐỔI MỚI SÁNG TẠO

Lọc theo danh mục
  • Năm xuất bản
    Xem thêm
  • Lĩnh vực
liên kết website
Lượt truy cập
 Lượt truy cập :  31,604,648
  • Công bố khoa học và công nghệ Việt Nam

76.03

Công nghệ sinh học trong y học

Nguyễn Hùng Cường, Bạch Thị Quỳnh, Phạm Văn Linh, Nguyễn Bảo Trân, Hoàng Thanh Huyền, Hoàng Thị Hải Yến, Trần Xuân Bách(1), Trần Thị Vượng, Azumi Ishizaki, Hiroshi Ichimura, Phạm Văn Thức

Nghiên cứu tỷ lệ đột biến gen kháng thuốc của HBV ở đối tượng tiêm chích ma túy và giá mại dâm tại Hải Phòng

Drug resistant hepatitis B virus mutants frequently appears among drug intravenous user (IDU) and female sex worker (FSW) groups in Haiphong, Vietnam

Y học Việt Nam

2013

0

314-320

1859-1868

Đột biến gen kháng thuốc, HBV, Tiêm chích ma túy, Gái mại dâm, Tỷ lệ nhiễm, Nghiên cứu, Hải Phòng

Objective: To confirm drug resistant hepatitis B virus mutants frequently appear among drug intravenous user (IDU) and female sex worker (FSW) groups in Haiphong, Vietnam. Subject and methods: Plasma samples were collected from 633 subjects among two groups (IDU: 492; FSW: 141) in the Rehabilitation Center in Haiphong. Plasma viral DNA was extracted from samples that were positive for hepatitis B suface antigen (HBsAg). Pol-RT regions of HBV were amplified by PCR with primers (HB1F(18-39)/HB1R(534-557) and HB2F(414-433)/HB2R(970-989)). PCR products were sequenced directly and analized by GENTYX program, introduction of Standford University. Results and conclusions: HBsAg prevalence was 10,57 percent and 10,64 percent among IDU and FSW groups in Haiphong. Three HBV genotypes/subtypes were confirmed, subtypes B4 was predominant (79.87 percent), follow by subtypes C1 (18.87 percent) and subtypes I1 (1,26 percent). Two subtypes I1 strains were indentied. Subtype I1 was identified with very rarely prevalence in Vietnam. Lamivudine resistant rate was 3,84 percent (L80I mutation: 1,92 percent; M204I mutation: 1,92 percent) and tenofovir resistant rate was 1,92 percent (M204I mutation). The resistant rate of adefovir and entercavir was 0 percent. M204I mutation (YMDD =YIDD) was cross-resistant mutation, HBV will resistant with lamivudine, tebivudine and tenofovir. The appearence of cross-resistant mutations can expect treatment failure with multi-drugs in future. The buiding a national program to monitor the appearence HBV drug resistant mutations is very importance.

TTKHCNQG, CVv46

Xem toàn văn